Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
Follicular Lymphoma
Explore 197 assets in Follicular Lymphoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07355283CT.gov IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Follicular Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa (this asset) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | P3 | B · 60 |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Romidepsin | City of Hope Medical Center | P2 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2/3 | BBB |
| Recombinant Human Hyaluronidase | National Cancer Institute (NCI) | P3 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Etoposide | David Bond, MD | P3 | BB |
| Rituximab | Sun Yat-sen University | P4 | BB |
+42 more in the Follicular Lymphoma cohort
Other indications for Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa in Follicular Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-signal-regulatory-protein-alpha-sirp-alpha-variant-v2-extracellular-d1-domain-sirp-alpha-v2d1-fragment-31-163-comprising-the-first-two-extracellular-loops-of-the-d1-domain-nsup110supasup80sup-variant-anti-human-cd47-integrin-associated-protein-iap-1-133-in-the-current-sequence-fused-via-a-g4s-2-peptide-linker-134-143-to-gamma-1-heavy-chain-144-594-vh-mus-musculus-ighv1-1201-ighd-ighj101-cdr-kabat-51712174-178193-209242-253-144-264-homo-sapiens-ighg103ch1-265-362-hinge-363-377-ch2-ssup445supa-esup480supa-k-sup481supa-378-487-ch3-488-592-chs-593-594-265-594-367-213-disulfide-with-kappa-light-chain-1-213-v-kappa-mus-musculus-igkv4-7201-igkj101-cdr-kabat-1079-24-3349-5588-96-1-106-homo-sapiens-igkc01-107-213-dimer-373-373376-376-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-cell-line-cho-k1-glycoform-alfa-follicular-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →